Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) posted its quarterly earnings data on Thursday. The company reported a 95% complete response rate at any time and a 76% durable complete response rate at 12 months, with favorable safety and tolerability. Relmada Therapeutics has a 12-month low of $0.55 and a 12-month high of $8.00. HC Wainwright assumed coverage on Relmada Therapeutics in a research report on Thursday, June 18th. Featured StoriesReceive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.